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Echinococcosis is among the most neglected parasitic diseases. Development of new drugs and other treatment modalities receives
very little attention, if any. In most developed countries, Cystic Echinococcosis (CE) is an imported disease of very low incidence
and prevalence and is found almost exclusively in migrants from endemic regions. In endemic regions, predominantly settings
with limited resources, patient numbers are high. Whole communities do not have access to appropriate treatment. The choice
of treatment modalities is limited because of poor infrastructure and shortage of equipment and drugs. In this context, CE meets
the criteria for a neglected disease. Furthermore, the terminology related to the designations around the parasite, its evolution
and some therapeutic procedures is not uniform and sometimes inappropriate terms and wrong designations are used based on
incorrect concepts. Although all of us know the diﬀerent aspects of the disease it is pertinent to remember some important points
and, above all, to clarify some aspects concerning the hydatid cyst’s nomenclature in order to understand better the therapeutic
options in the liver locations, particularly the diﬀerent surgical approaches.
1.Introduction
I have frequently noticed both, in published articles and
also in communications during scientiﬁc meetings, the
use of wrong designations concerning the hydatid cyst,
a designation used for Cystic Echinococcosis. It is not a
diﬀerent nomenclature but the use of inappropriate terms,
which are based on incorrect concepts. I think it would be
useful, for all of us, to use the same nomenclature. It is
absolutely necessary that the nomenclature is correct and
universally accepted. So, I think it is pertinent to write this
paper in order to remember some important points and,
above all, to clarify some aspects concerning the hydatid
cyst’s nomenclature.
Human Echinococcosis is a zoonotic infection caused
by larval forms (metacestodes) of tapeworms of the
genus Echinococcus found in the small intestine of carni-
vores. Although there are diﬀerent species of Echinococ-
cus described, only four of them—E. granulosus, E. mul-
tilocularis, E. oligarthrus and E. vogeli—are recognized
as taxo-nomically relevant, and only the ﬁrst two are
pathogenic for humans. To distinguish the diseases caused
by these two diﬀerent species, the World Health Organiza-
tion (WHO) proposed the designation Cystic Echinococ-
cosis (CE) for the disease caused by E. granulosus and
Alveolar Echinococcosis (AE) for the disease caused by
E. multilocularis.
The annual incidence of CE can range from less than
1 to 200 per 100,000 inhabitants in various endemic areas
[1]. In China and Central Asia the number of population
risk is more than 20 million people [2]. The mortality rate
(about 2–4%) from CE is lower than that from AE but it
may increase considerably if medical treatment and care is
inadequate [1].
The annual incidence of AE is generally low in most
of the endemic areas (0,03–1,2 per 100,000 inhabitants)
but in untreated or in inadequately treated patients
mortality is more than 90% within 10/15 years of diagnosis
[1, 3].
Despite these important data and the socioeconomic
impact [4–6], Echinococcosis remains a neglected disease
[7].2 Gastroenterology Research and Practice
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Figure 1: Vital cycle of E. granulosus.
2. Cystic Echinococcosis
Cystic Echinococcosis is the most frequent, and in the E.
granulosus vital cycle (Figure 1) we consider the adult tape
worm, which lives in the intestine of some carnivores (called
deﬁnitiveorﬁnalhosts),andthelarvalphasethatdevelopsin
the herbivores (intermediate hosts). The intermediate hosts,
in which humans are included, are infected by ingestion of
eggs within the faeces of the deﬁnitive hosts. Hydatid cyst or
Hydatidosis is the designation for the larval phase of the E.
granulosus.
InprimaryEchinococcosis,metacestodescystsdevelopin
various sites from oncospheres after ingestion of E. granulo-
sus eggs. In secondary Echinococcosis, larval tissue spreads
from the primary site and proliferates after spontaneous
or trauma-induced cyst rupture or after release of viable
parasite material during invasive treatment procedures.
3.HydatidCyst
3.1. Deﬁnition. The hydatid cyst (Figure 2) is composed by
two parts: the echinococcal parasite (or hydatid) and the
adventitiathatinvolvesit,asDev´ edeﬁnedinthebeginningof
the last century (1911), and there is no reason or legitimacy
to modify this deﬁnition.
The adventitia is a layer of an inert tissue with ﬁbrosis
and variable thickness, which results from the host’s organ
reaction against the hydatid, which is a foreign body. This
layer can be called periparasitic or perihydatidic area, but
never pericystic area, as it is sometimes wrongly named,
because it is an integrant part of the cyst. An example of this
common mistake is the use of the term “pericystectomy” for
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Figure 2: Hydatid cyst of the liver (scheme).
the excision of a cyst, when removing the adventitia. This
term misleads you into thinking that this layer (adventitia)
is not part of the cyst, assuming that the cyst includes only
the parasite (hydatid) and not the adventitia, which is wrong
and opposite to Dev´ e’s deﬁnition [8, 9].
3.2. Course of Infection and Organ Localization. The eggs of
these tapeworms excreted by carnivores may infect various
species of natural intermediate host animals and humans.
During the natural course of infection, the fate of the
hydatid cysts is variable. Some cysts may grow (average
increase: 1–30mm per year) and persist without a noticeable
change for many years. Others may spontaneously rupture
or collapse and can completely disappear. Calciﬁed cysts are
not uncommon. Spillage of viable protoscolices after spon-
taneous or traumatic cyst rupture, or during interventional
procedures, may result in secondary Echinococcosis.
After an undeﬁned and variable incubation period,
infections may become symptomatic if active cysts exert
pressure on adjacent tissue and induce other pathologic
events. Usually cysts do not induce clinical symptoms
until they have reached a particular size. Sudden onset of
symptoms may be due to cyst rupture.
InprimaryEchinococcosisthemetacestodesmaydevelop
in almost any organ. Most patients (up to 80%) have a
single organ involved and harbour a solitary cyst, localized
in approximately two-thirds of cases in the liver and in about
20% in the lungs.
3.3. Cyst Composition and Evolution. The hydatid is a sphere
composed of two membranes with liquid in its interior
(Figure 2). The inner layer is called germinal membrane and
the outer layer is called laminated membrane. The germinal
membrane (20–25 micron of thickness) is composed by
embryonic cells. Its function is to elaborate the diﬀerent
elements of the hydatid. The laminated membrane, which
is formed from the previous one, is a white coloured
membrane with quitine, and formed by several concentric
layers of polysaccharide material. Brood capsules, which
contain protoscolices and scolices, develop from germinal
layer through a clone mechanism assuring the fertility of the
cyst.Scolicesarejustintussusceptionsheadsoftaenia,sothey
have got proboscis and hooks too.Gastroenterology Research and Practice 3
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Figure 3: WHO US classiﬁcation of hydatid cysts.
The hydatid liquid is clean and clear, “as well as the
clean water from its natural source”, containing secretions
from both the parasite and host and all the elements from
the “inner wall” of the cyst, named hydatid sand. It has an
identical composition to that of the host’s serum (Na, K, Cl,
CO2, a density between 1.008 and 1.015, alkaline pH) and
some proteins that confer antigenic properties.
Through the slow evolution of a cyst, several events can
occur: the death of the parasite due to dysfunction of the
germinal membrane (detachment or aging), the “cyst’s wall”
ﬁssure due to detachment of membranes or micro trauma-
tisms, the transformation of scolices into vesicles (vesicula-
tion) attempting to preserve the specie. These new vesicles,
which live into the hydatid ﬂuid, must be called oﬀspring or
“daughter” vesicles (The term “daughter cysts” is incorrect,
since the cysts do not have daughters, but only the vesicles).
Thesedaughtervesicleshavethesameconstitutionaswellthe
same mission of the vesicle mother. So, in this way, protosco-
lices may evolutes into either a new cyst or an adult parasite.
The long-term survival of the hydatid indicates the exis-
tence of protection mechanisms against immunity response
of the host. The hydatid ﬂuid is the main factor responsible
for the antigenic stimulation, but the germinal layer of the
cyst is a barrier against immune competent cells of the host.
So, it is necessary to have damages in the germinal layer, like
ﬁssuresorrupture,togetanantigenicstimulation.Whenthis
antigenic stimulation occurs, there is a continuous elevation
of the immunologic values for an indeterminate time. This
elevation also happens after the cyst manipulation (surgery,
puncture, etc.).
4.HydatidCystof the Liver
4.1.Ultrasound(US)Classiﬁcation. In1981ProfessorGharbi
et al. proposed a US classiﬁcation of the hydatid cysts [10].
In his classiﬁcation, he considers ﬁve types according the
natural evolution of the parasite. After him other authors
proposed their own classiﬁcations (Beggs [11]; Lewall and
McCorkell [12]; Caremani et al. [13]; Perdomo et al. [14];
Shambeshetal.[15]),whichwerenothingbutamodiﬁcation
of the classiﬁcation proposed by Gharbi. So, in 1995 the
Informal Working Group on Echinococcosis (IWGE-WHO)
proposed the standardization of the US classiﬁcation. This
task, coordinated by Call Macpherson, ends in a new classi-
ﬁcation, known as WHO classiﬁcation, which was published
in 2003 [16] ,b u ti tw a sn o tu n i v e r s a l l ya c c e p t e d ,d u et ot w o
main reasons:
(i) thediﬃcultytoclassifysomecysts,normallyincluded
in type 3,
(ii) the inclusion of all type 4 cysts as inactive (in some of
them we found daughter vesicles or fertile liquid).
In order to contribute for a clariﬁcation of the ﬁrst point,
it is proposed to divide the type 3, considering a type 3a and
at yp e3 b ,a sr e p r e s e n t e di nFigure 3 [17, 18]. For cysts type 4
was proposed a new approach: “watch & wait” [17, 18].
On the other hand all we know how it is diﬃcult to
deﬁne the cyst inactivity, particularly to quantify the cyst
content solidiﬁcation. To contribute for the deﬁnition of cyst
inactivity, I will try to establish the criteria, based on the cyst
solidiﬁcation, and the way for the quantiﬁcation of the cyst’s
content solidiﬁed percentage.
4.2. Therapeutic Options/Nomenclature. The aim of the
hydatid cyst treatment is the death of the parasite and
consequently the cure of the disease [19–21]. It has to be
done with a minimal risk and maximum comfort for the
patient, and always paying attention to avoid complications,
secondary hydatidosis, and relapses.
The methods to achieve the death of the parasite are both
thesterilizationofthecystcontent,usingscolicidalagents,or4 Gastroenterology Research and Practice
theparasitedirectremoval,throughaspirationorthesurgical
excision of the entire cyst [17–21].
4.2.1. Sterilization of the Cyst. This method is based on
the degeneration of the germinal hydatid membrane and
destruction of the viable elements of the hydatid ﬂuid, due
to the scolicidal drugs eﬀect, whatever injected into the cyst
or orally taken, or by thermal ablation (radiofrequency).
(a) Injection of a Scolicidal Solution into the Cyst Cavity. This
is the most ancient method of treatment for the hepatic
cysts [9]. It was considered the best method for treatment
of simple cysts (univesicular cysts, types 1 and 3 in the actual
ultrasound classiﬁcation). This method consists in puncture
of the cyst and aspiration of part of the content to allow the
introduction of the scolicidal solution. This solution must
stayinthecysticcavityduring, atleast,10minutes. Afterthat
the cystic cavity is totally aspirated. In the past this approach
was only done by laparotomy, but nowadays we have two
more approaches: laparoscopy and percutaneous puncture.
Percutaneous puncture is known as PAIR (Puncture,
Aspiration,Injection(ofthescolicide)andReaspiration)and
it is considered the Gold Standard [17, 18, 22–24]; since
it is a minimal invasive technique, it is less painful to the
patient as well as it has an inferior complication rate; it is
less expensive with earlier discharge and activity resumption
[17, 18, 23, 25–29].
(b)OralAdministrationofScolicidalDrugs. Nowadaysalben-
dazole is the drug chosen for oral treatment of hydatid
cysts [30–36]. Its metabolite, the albendazole sulphoxid, is
the active component with a half-life of 8.5 hours [37–39].
Albendazole is orally administered, every 12 hours, in a total
dose of 10–15mg/kg/day, during a period called a therapeu-
ticcycle.Theminimalperiodoftreatmentconsistsinawhole
cycle, which can be repeated if necessary [17, 31, 40, 41]. The
scolicide’s eﬀect depends on the stage of development of the
hydatid and on its germinal membrane integrity too (more
eﬀective on young cysts—type 1 and less on type 2 cysts with
over 50% of failure rate) [20, 31]. Albendazole is also used
in surgery to reduce the internal cyst’s tension and prevents
secondary hydatidosis [17, 18, 42, 43].
(c) Radiofrequency Thermal Ablation. Radiofrequency ther-
mal ablation has proved to be a safe method to destroy the
germinal layer [17, 18, 44, 45]. This method can be done
by percutaneous approach using the same kind of needle-
electrode employed in the ablation of liver tumors. Because
the contents of the cyst are destroyed by heat rather than
a chemical agent, the procedure is simpler than the PAIR
treatment since it avoids the need to inject a scolicidal agent
[44, 45]. However, further investigations are needed to be
carried out before it can be recommended as an eﬀective
percutaneous treatment.
4.2.2. Parasite Removal. There are two diﬀerent ways to
remove the parasite: the aspiration of the parasite (or
hydatid) procedure called Hydatidectomy or the excision of
the cyst, which necessarily removes the parasite, procedure
called Cystectomy.
(a)Hydatidectomy. Thisisaprocedurethatonlyremovesthe
hydatid (parasite). It is identical to the puncture method to
thesterilizationofthecystexceptinginwhatconcernsthelast
step (total aspiration), which is done under high pressure,
in order to remove the hydatid membranes and all the
remaining contents [9, 17, 46]. This method (conservative
procedure) can be performed under laparotomic, laparo-
scopic, or percutaneous approach. Percutaneous approach is
called PEvac (Puncture and Evacuation) and is considered
the Gold Standard once it is a minimal invasive technique,
it is less painful for the patient, as well as it has less
complication rate and less expensive, with earlier discharge
and activity resumption [47, 48].
(b) Cystectomy. Cystectomy consists on the excision of the
cyst, which ideally should be total, in order to diminish
relapses and complications [9, 17–19, 46, 49]. It can be
performedthroughlaparotomyorlaparoscopy,bothbyopen
orclosedmethods.Inbothoptions,thedissectionismadeon
the outside of the adventitia. In the past this dissection was
made in sane hepatic tissue to guarantee the complete cyst
removal: the parasite (hydatid) and the host tissue that sur-
roundsit(adventitia),butaftertheworksofPengXinYu,the
dissection is made in the virtual space between the adventitia
and sane hepatic tissue, which is a less bloody space [50].
The open method is performed by opening the cyst, then
itsaspirationandﬁnallytheremovalofitscontent.Onlyafter
this step we proceed to the entire cyst “wall” removal [9, 17,
18, 46, 51–53].
The closed method, known as Napalkoﬀ’s procedure,
consists of the entire removal of the cyst without opening
it. When a total resection can damage bilious or vascular
structures, must a partial cystectomy be done, despite this is
a conservative procedure [9, 17, 18, 46, 51, 52].
Cystectomy can be performed by a video-assisted surgery
on selected cases [17, 53–59], namely, small cysts (<5cm
in diameter) with peripheral localization. Since the total
cystectomy is the ideal approach, it should be done by the
closed method and without using CO2 due to dissemination
risk in case of rupture [58].
Another option is the hepatic resection (segmentectomy
or lobectomy), in case of great size cysts in which there is a
high risk of ischemia for the remained hepatic tissue [17, 46,
51–53]. So, hepatic resection is an option only for selected
cases.
The main advantage of cystectomy is the immediate
healingofthedisease,whichisobtainedonlywhenthecystis
completely removed whatever with or without hepatic tissue
(cystectomy or hepatic resection). Both methods, called
radicalprocedures,havehigherrisksper-operativelybutfewer
rates of complications and relapses after surgery. On the
other side, conservative methods have less intraoperatively
risks but higher rate of long outcome complications and
relapses.
Although nowadays the morbidity and mortality of
the hydatid cyst surgery have diminished, they cannot beGastroenterology Research and Practice 5
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Figure 4: Hydatid cyst of the liver submitted to PAIR: (a) Immediately after PAIR; (b) 3 months later; (c) 1 year later.
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Figure 5: Hydatid cyst of the liver treated with Albendazole: (a) After 1 cycle (3 month); (b) 6 months later; (c) 18 months later.
overlooked. The prevention of complications starts with an
accurate surgical technique and the necessary caution in the
removal of the cysts which are very close to the bilious and
vascular intrahepatic structures.
To prevent the relapses, it is very important to protect
the surgical ﬁeld with pads soaked with scolicidal solution
[9,17–19,46,51,52,58–60].Thisprocedurewillalsoprevent
a secondary hydatidosis in case of spillage of the cyst content
during the cyst removal.
5.Deﬁnition ofCystInactivity
It is diﬃcult to deﬁne the cysts inactivity as well as to
evaluate the therapeutic eﬃcacy, particularly chemotherapy
and percutaneous puncture, which is based on US images.
US permit controlling the cyst evolution after the treatment
showing the progressive degeneration of its content until the
parasite’s death [10, 16, 23, 27, 31]. The interpretation of the
US images is very important to clarify the parasite activity
stage, in order to evaluate the treatment success.
P a t i e n t ss u b m i t t e dt oP A I Ra r ee v a l u a t e do n ew e e kl a t e r ,
in the ﬁrst and third months, and after that each six months
until ranging the inactive stage [23, 27]. In case of anti-
infective therapy (Albendazole), the control is done during
the ﬁrst and third months and after that each six months.
Once the cysts range the inactive stage, they are evaluated
each year in both approaches.
Each observation of the US images is evaluated and
compared to the previous one. If there are not any signiﬁcant
alterations, to the previous images, or if we ﬁnd a persistent
liquid image, it is not considered the treatment of eﬃcacy.
The ﬁrst signal of the therapeutic eﬃcacy is the
parasite membranes detaching from the cyst adventitia.
These signals are evident in the US images immedi-
ately after the ﬁnal aspiration in the percutaneous treat-
ment (Figure 4(a)) and after the ﬁrst chemotherapy cycle
(Figure 5(a)).
In the subsequent US images, we should observe alter-
ations on cyst content, such as the diminution of the liquid
area and its substitution by solid patron giving the cyst
a pseudotumoral aspect (Figures 4(b) and 5(b)). The cyst
content solidiﬁcation must continue until the almost total
solidiﬁcation (Figures 4(c) and 5(c)) that allows aﬃrming
that the cyst is inactive.
If a simple cyst, according to its US characteristics,
after the therapeutic approach, appears with the membranes
detached,itmeansthatitevolutesfromanactivestage(fertile
cyst) to a transitional stage (degenerated cyst). This is the
proof of the therapeutic eﬃcacy. If, in its evolution, we
observe a progressive reduction of the liquid content, like the
i m a g e s( b )o fF i g u r e s4 and 5,w ec a na ﬃrm that the thera-
peutic is successful. Finally if the cyst ranges a heterogeneous
patron, mainly solid like the images (c) of Figures 4 and 5,i t
means the cyst ranged the inactive stage, which corresponds
to a content solidiﬁcation greater than 75%.
We can also observe the cyst vanishing (Figure 6(a))
or the existence of vestiges, like a linear echoic scare
(Figure 6(b)).6 Gastroenterology Research and Practice
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Figure 6: Hydatid cyst of the liver after treatment: (a) Cyst vanishing; (b) Cyst vestiges.
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Figure 7: Hydatid cyst of the liver after treatment: 55% content solidiﬁcation.
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Figure 8: The same cyst of Figure 7, one month after (75% solidiﬁcation).
(a) (b) (c)
Figure 9: The same cyst of Figure 7, six month later (solidiﬁcation > 90%).Gastroenterology Research and Practice 7
Resuming, the criteria for the therapeutic eﬃcacy evalu-
ation are
(a) parasite’s membranes detachment immediately after
percutaneous treatment and after the ﬁrst cycle of
chemotherapy,
(b) modiﬁcation of the US patron of the cyst content
withtheprogressivesubstitutionoftheliquidcontent
by a solid patron,
(c) cyst vanishing or observation of a linear echoic scare
(vestiges).
6. Method for Quantiﬁcation of
the Solidiﬁed Percentage
Once the cyst content solidiﬁcation is the criterion to
evaluate the therapeutic eﬃcacy, and a solidiﬁed area greater
than 75% presumes the parasite inactivity, it is necessary to
quantify, so precisely as possible, this solidiﬁed area. In order
to obtain this value, we should proceed as follows:
(1) digitalisation of the US images and selection of the
cystic area ((b) images of Figures 7, 8,a n d9),
(2) ﬁlter application, by Adobe Photoshop programme,
to select the liquid and solid areas of the cyst ((c)
images of Figures 7, 8,a n d9),
(3) image“vectorization”byaComputerAssistedDesign
(CAD) programme for calculation of the percentage
of the solidiﬁed area.
By this way, it is possible to know the exact moment at
which a cyst under chemotherapy or submitted to percuta-
neous puncture ranged the inactive stage and, according the
samecriteria,toknowifthetherapeuticisbeingsuccessfulor
not.ThisinformationisachievedbyUS,whichhasarelevant
role to evaluate the treatment eﬃcacy in the liver hydatid
cysts, particularly in the cysts treated by anti-infective drugs
(chemotherapy) or submitted to percutaneous puncture,
because it allows controlling the cyst evolution after the
treatment, showing the progressive degeneration of its
content until it ranges an almost total or total solidiﬁcation,
which proofs its inactivity and consequently the parasite’s
death.
This imaging method is the only way that allows us to
aﬃrmthesuccessofthetreatmentandthecureofthedisease.
The therapeutic eﬃcacy of the liver hydatid cysts can only be
evaluated by imaging methods once it is not yet available by
immunological means.
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